This invention relates to a novel molecular based method that enables the screening of twin-to-twin transfusion syndrome (TTTS), in a fast and non-invasive way. This method relies on the quantification of a specific biomarker gene expression on maternal plasma /Figure 1). Therefore it is proposed as a screening tool for TTTS that will eventually contribute to an antecipation of the diagnosis and consequently to a substantial decrease of the underlying fetal mortality and morbidity.


Twin-to-twin transfusion syndrome (TTTS) is a serious condition that affects 10% to 15% of twin pregnancies with monochorionic placentation. Early TTTS can be managed conservatively. However, without or with a therapeutic intervention, TTTS is often associated to a high perinatal loss rate (death of at least one of the twins) and risk of severe neurologic impairment among survivors, which makes the time of diagnosis extremely important. Currently, imaging methods are used after 16 weeks of gestation. Therefore, a reliable and accurate tool able to screen TTTS prior to this time point may constitute an important improvement in the survival and prognosis of both twins


This is a fast and non-invasive molecular-based method. The method may antecipate the diagnosis and allow a more timely treatment and consequently greater probabilities of survival of both fetuses and decreasing sequelae in survivors. 

Potential comercial use/applications: 

Non-invasive molecular diagnostic/screening devices.